{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1364233269763533952.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.blre.2020.100672"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0268960X20300229?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0268960X20300229?httpAccept=text/plain"}}],"dc:title":[{"@value":"Targeting MCL-1 in hematologic malignancies: Rationale and progress"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1384233269763533962","@type":"Researcher","foaf:name":[{"@value":"Andrew H. Wei"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533959","@type":"Researcher","foaf:name":[{"@value":"Andrew W. Roberts"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533956","@type":"Researcher","foaf:name":[{"@value":"Andrew Spencer"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533958","@type":"Researcher","foaf:name":[{"@value":"Aaron Seth Rosenberg"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533954","@type":"Researcher","foaf:name":[{"@value":"David Siegel"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533961","@type":"Researcher","foaf:name":[{"@value":"Roland B. Walter"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533952","@type":"Researcher","foaf:name":[{"@value":"Sean Caenepeel"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533957","@type":"Researcher","foaf:name":[{"@value":"Paul Hughes"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533955","@type":"Researcher","foaf:name":[{"@value":"Zach McIver"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533953","@type":"Researcher","foaf:name":[{"@value":"Khalid Mezzi"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533960","@type":"Researcher","foaf:name":[{"@value":"Phuong Khanh Morrow"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233269763533963","@type":"Researcher","foaf:name":[{"@value":"Anthony Stein"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0268960X"}],"prism:publicationName":[{"@value":"Blood Reviews"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2020-11","prism:volume":"44","prism:startingPage":"100672"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://creativecommons.org/licenses/by-nc-nd/4.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0268960X20300229?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0268960X20300229?httpAccept=text/plain"}],"createdAt":"2020-02-21","modifiedAt":"2025-10-02","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360017282465520128","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025430215202944","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The tubulin polymerization inhibitor gambogenic acid induces myelodysplastic syndrome cell apoptosis through upregulation of Fas expression mediated by the NF-κB signaling pathway"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092386749312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine"}]},{"@id":"https://cir.nii.ac.jp/crid/1360581934839883648","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360588379399078400","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A New Histology-Based Prognostic Index for Acute Myeloid Leukemia: Preliminary Results for the “AML Urayasu Classification”"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.blre.2020.100672"},{"@type":"CROSSREF","@value":"10.1111/cas.15458_references_DOI_SAK0i1d58kISsyF1VgxEeR375El"},{"@type":"CROSSREF","@value":"10.1080/15384047.2024.2427374_references_DOI_SAK0i1d58kISsyF1VgxEeR375El"},{"@type":"CROSSREF","@value":"10.1186/s12885-020-07469-x_references_DOI_SAK0i1d58kISsyF1VgxEeR375El"},{"@type":"CROSSREF","@value":"10.1038/s41598-023-41230-1_references_DOI_SAK0i1d58kISsyF1VgxEeR375El"},{"@type":"CROSSREF","@value":"10.3390/jcm14061989_references_DOI_SAK0i1d58kISsyF1VgxEeR375El"}]}